ZA954925B - Delivery of therapeutic agents to receptors using polysaccharides - Google Patents

Delivery of therapeutic agents to receptors using polysaccharides

Info

Publication number
ZA954925B
ZA954925B ZA954925A ZA954925A ZA954925B ZA 954925 B ZA954925 B ZA 954925B ZA 954925 A ZA954925 A ZA 954925A ZA 954925 A ZA954925 A ZA 954925A ZA 954925 B ZA954925 B ZA 954925B
Authority
ZA
South Africa
Prior art keywords
polysaccharides
receptors
delivery
therapeutic agents
therapeutic
Prior art date
Application number
ZA954925A
Other languages
English (en)
Inventor
Ernest V Groman
Edward T Menz
Philip M Enriquez
Chu Jung
Jerome M Lewis
Lee Josephson
Original Assignee
Advances Magnetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advances Magnetics Inc filed Critical Advances Magnetics Inc
Publication of ZA954925B publication Critical patent/ZA954925B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0442—Polymeric X-ray contrast-enhancing agent comprising a halogenated group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1808—Catalysts containing secondary or tertiary amines or salts thereof having alkylene polyamine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1816—Catalysts containing secondary or tertiary amines or salts thereof having carbocyclic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/1825—Catalysts containing secondary or tertiary amines or salts thereof having hydroxy or primary amino groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
    • C08G18/20—Heterocyclic amines; Salts thereof
    • C08G18/2009—Heterocyclic amines; Salts thereof containing one heterocyclic ring
    • C08G18/2036—Heterocyclic amines; Salts thereof containing one heterocyclic ring having at least three nitrogen atoms in the ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/22—Catalysts containing metal compounds
    • C08G18/24—Catalysts containing metal compounds of tin
    • C08G18/244—Catalysts containing metal compounds of tin tin salts of carboxylic acids
    • C08G18/246—Catalysts containing metal compounds of tin tin salts of carboxylic acids containing also tin-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/22—Catalysts containing metal compounds
    • C08G18/26—Catalysts containing metal compounds of lead
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/04—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent
    • C08J9/12—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
    • C08J9/14—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent organic
    • C08J9/143—Halogen containing compounds
    • C08J9/144—Halogen containing compounds containing carbon, halogen and hydrogen only
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2101/00—Manufacture of cellular products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
    • C08J2375/04—Polyurethanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Signal Processing (AREA)
  • Ceramic Engineering (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA954925A 1994-06-16 1995-06-14 Delivery of therapeutic agents to receptors using polysaccharides ZA954925B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,551 US5554386A (en) 1986-07-03 1994-06-16 Delivery of therapeutic agents to receptors using polysaccharides

Publications (1)

Publication Number Publication Date
ZA954925B true ZA954925B (en) 1996-02-13

Family

ID=22989623

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA954925A ZA954925B (en) 1994-06-16 1995-06-14 Delivery of therapeutic agents to receptors using polysaccharides

Country Status (7)

Country Link
US (1) US5554386A (zh)
KR (1) KR970703785A (zh)
CN (1) CN1092987C (zh)
AU (1) AU2700195A (zh)
IL (1) IL114116A0 (zh)
WO (1) WO1995034325A1 (zh)
ZA (1) ZA954925B (zh)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
TW520293B (en) * 1995-11-22 2003-02-11 Univ Johns Hopkins Med Delivery system to enhance cellular uptake of biomolecules
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6303584B1 (en) * 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
JP2001511811A (ja) * 1997-02-13 2001-08-14 ボーン ケア インターナショナル インコーポレイテッド ビタミンｄ化合物の標的治療放出
ATE317703T1 (de) 1997-06-12 2006-03-15 Innovata Plc Polymer-wirkstoff-konjugate zur behandlung von krebs
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
ES2245805T3 (es) * 1997-10-03 2006-01-16 Galenica Pharmaceuticals, Inc. Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
US6245316B1 (en) 1997-10-08 2001-06-12 David Platt Enhancement of delivery of radioimaging and radioprotective agents
JP2002513028A (ja) 1998-04-28 2002-05-08 ガレニカ ファーマシューティカルズ， インコーポレイテッド ポリサッカリド抗原結合体
JP2003507345A (ja) * 1999-08-10 2003-02-25 エムエル ラボラトリーズ ピーエルシー デキストリン溶液を使用した治療薬剤の送達方法
US20030039960A1 (en) * 2000-01-13 2003-02-27 Ml Laboratories Plc Therapeutic treatment
IT1318403B1 (it) 2000-03-17 2003-08-25 Cooperativa Ct Ricerche Poly T Esteri polisaccaridici di n-derivati di acido glutammico.
CN1095472C (zh) * 2000-04-17 2002-12-04 上海复康医药科技发展有限公司 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
US6991817B2 (en) 2000-06-29 2006-01-31 Pharmagenesis, Inc. Acid-modified arabinogalactan protein composition
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
EP1337830A2 (en) 2000-12-01 2003-08-27 Auburn University Use of acacia gum (arabic gum) to isolate and preserve biological material
US7521433B2 (en) * 2001-03-13 2009-04-21 Japan Science And Technology Agency Gene carriers with the use of polysaccharide and process for producing the same
US6896894B2 (en) 2001-10-30 2005-05-24 Battelle Memorial Institute Proteins stabilized with polysaccharide gums
CN100579577C (zh) 2002-03-15 2010-01-13 退伍军人事务研发服务部 使用细胞脱唾液酸决定簇和糖缀合物将细胞靶向组织和器官的方法和组合物
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
MXPA05003843A (es) * 2002-10-10 2006-02-17 Us Dept Veterans Affairs Deteccion, localizacion y determicnacion de fases de tumores usando linfocitos activados rotulados dirigidos a un epitope especifico.
US20040209801A1 (en) 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
AU2004219595A1 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
CA2528136A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CA2559188C (en) 2004-03-05 2013-01-08 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid-methotrexate conjugate
US7807675B2 (en) * 2004-04-02 2010-10-05 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid-methotrexate conjugate
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
MX2007006365A (es) * 2004-11-30 2007-06-20 Veritron Ltd Mejorador del efecto de adrenocorticoide, que comprende goma arabiga.
EP1830902A2 (en) * 2004-12-30 2007-09-12 Cinvention Ag Combination comprising an agent providing a signal, an implant material and a drug
SI1836239T1 (sl) * 2005-01-13 2009-04-30 Cinv Ag Kompozitni materiali, ki vsebujejo ogljikove nanodelce
CN101142149A (zh) * 2005-03-18 2008-03-12 金文申有限公司 制备多孔烧结金属材料的方法
JP5296531B2 (ja) 2005-05-05 2013-09-25 センシエント フレイバーズ エルエルシー βグルカン及びマンナンの製造
CN101212990A (zh) * 2005-07-01 2008-07-02 金文申有限公司 包含网状复合材料的医疗器械
AU2006303324A1 (en) * 2005-10-18 2007-04-26 Cinvention Ag Thermoset particles and methods for production thereof
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
CN101002947B (zh) * 2007-01-16 2010-08-25 湖南农业大学 一种用于细菌病治疗的靶向药物及其制备方法
WO2008087214A1 (en) * 2007-01-19 2008-07-24 Cinvention Ag Porous, non-degradable implant made by powder molding
US20080213742A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system
WO2008104599A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system bag
CN102300576B (zh) 2008-12-15 2014-03-05 美国医科华股份有限公司 用包含黄芪提取物的组合物治疗特发性血小板减少性紫癜
EP2432499A2 (en) 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
CN102380109B (zh) * 2011-10-26 2013-07-24 四川大学 一种两亲性多糖包裹超顺磁纳米粒子构建的磁共振造影剂及其制备方法
AU2012334825B2 (en) * 2011-11-09 2017-08-24 Ascend Biopharmaceuticals Ltd Immunomodulatory conjugates
WO2014176389A1 (en) 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
TWI689310B (zh) 2014-07-11 2020-04-01 巨生生醫股份有限公司 治療鐵缺乏症之方法
KR20170054429A (ko) 2014-09-03 2017-05-17 제네세규스 인코포레이티드 치료용 나노입자 및 관련 조성물, 방법, 및 시스템
MX2022009419A (es) 2020-01-31 2022-08-25 Avilar Therapeutics Inc Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
CN111569083B (zh) * 2020-05-25 2024-09-27 杭州濡湜生物科技有限公司 一种适用于抗非洲猪瘟病毒siRNA药物的靶向载体及其应用
JP2024517812A (ja) 2021-05-03 2024-04-23 アヴィラー セラピューティクス インコーポレイテッド 免疫グロブリン及びその他のタンパク質を分解する強力なａｓｇｐｒ結合性化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US336506A (en) * 1886-02-16 brinkerhoff
US2649421A (en) * 1949-11-22 1953-08-18 Dextran Ltd Synthetic substances of the polysaccharide type
US2765244A (en) * 1951-03-19 1956-10-02 Dextran Ltd Process for degrading dextran in the presence of a reducing agent
GB2055847A (en) * 1979-07-30 1981-03-11 Bull F G Process for the production of carrier particles
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
CA1184492A (en) * 1981-01-14 1985-03-26 Masataka Morishita Preparation having excellent absorption property
EP0093757A1 (en) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
JPH0699482B2 (ja) * 1984-04-16 1994-12-07 ダイセル化学工業株式会社 多糖類誘導体
JPH0643441B2 (ja) * 1984-04-16 1994-06-08 ダイセル化学工業株式会社 多糖類誘導体
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
IT1177381B (it) * 1984-12-11 1987-08-26 Baldacci Lab Spa Metodo per la preparazione di coniugati della adenina-9-beta-d-arabino furano-side 5' monofosfato con albumina umana lattosaminata, coniugati risultanti e relative composizioi terapeuticamente attive
SU1285094A1 (ru) * 1985-01-21 1987-01-23 Сибирский научно-исследовательский институт целлюлозы и картона Способ обработки бумажной массы
DE3787403D1 (de) * 1986-05-09 1993-10-21 Pulverer Gerhard Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore.
US4861597A (en) * 1986-05-20 1989-08-29 Wako Pure Chemical Industries, Ltd. Novel functionallized liposomes and a process for production thereof
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5336506A (en) * 1986-07-03 1994-08-09 Advanced Magnetics Inc. Targeting of therapeutic agents using polysaccharides
DK172391B1 (da) * 1986-12-30 1998-05-18 Nihon Mediphysics Co Ltd Højmolekylær forbindelse til anvendelse som ikke-radioaktiv bærer, radioaktivt mærket højmolekylær forbindelse, fremgangsmåde til fremstilling deraf og fremgangsmåde til forbedret mærkning af en asialoglycoproteinacceptor-dirigerende forbindelse
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4946675A (en) * 1987-05-27 1990-08-07 Xoma Corporation Hepatic blocking agents
JPS6451198A (en) * 1987-08-21 1989-02-27 Telnite Ltd Modifying method for drilling soil
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
DE3734061A1 (de) * 1987-10-08 1989-04-20 Sandoz Ag Packung
DE3738069C2 (de) * 1987-11-09 1996-08-08 Hohenfellner Markus Mikroformkörper bzw. Mikroformkapsel sowie Vorrichtung für die regionale Applikation von Substanzen
JPH0816118B2 (ja) * 1988-02-03 1996-02-21 呉羽化学工業株式会社 抗ウイルス剤
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
US5041541A (en) * 1988-05-05 1991-08-20 The Procter & Gamble Company Functional sugar substituted with reduced calories
WO1990001295A1 (en) * 1988-08-04 1990-02-22 Advanced Magnetics, Incorporated Receptor mediated endocytosis type mri contrast agents
AU628403B2 (en) * 1988-09-29 1992-09-17 Access Pharmaceuticals, Inc. Methods and compositions for magnetic resonance imaging
CH682602A5 (de) * 1990-09-20 1993-10-15 Lawrence N Ehrsam Tonträgerhülle.
ES2059299T3 (es) * 1990-12-19 1997-10-01 Advanced Magnetics Inc Direccionado de agentes terapeuticos utilizando polisacaridos.
WO1993025239A1 (en) * 1992-06-17 1993-12-23 Advanced Magnetics Inc. Arabinogalactan derivatives and uses thereof

Also Published As

Publication number Publication date
CN1150761A (zh) 1997-05-28
CN1092987C (zh) 2002-10-23
WO1995034325A1 (en) 1995-12-21
US5554386A (en) 1996-09-10
IL114116A0 (en) 1995-10-31
AU2700195A (en) 1996-01-05
KR970703785A (ko) 1997-08-09

Similar Documents

Publication Publication Date Title
ZA954925B (en) Delivery of therapeutic agents to receptors using polysaccharides
AU1805499A (en) Method and apparatus for delivery of therapeutic agents to the heart
HUP9903489A3 (en) Use of epinastine for the preparation of pharmaceutical compositions treating pain
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
GB9506087D0 (en) Improvements relating to medical injection devices
AU1403199A (en) Local delivery of therapeutic agents
GB9415996D0 (en) Therapeutic agents
GB9416189D0 (en) Therapeutic agents
HK1028961A1 (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
GB9423460D0 (en) Therapeutic agents
GB2344530B (en) Coding of syringes to monitor their use
AU2193797A (en) Delivery of therapeutic agents to the prostate
GB9401879D0 (en) Therapeutic agents
EP1009236A4 (en) EVALUATION, ADMINISTRATION AND USE OF MEANS FOR THE TREATMENT OF HEART DISEASES
GB2292554B (en) Improvements relating to infusion devices
EP0850047A4 (en) METHODS OF USE AND COMPOSITIONS OF THERAPEUTIC LIPID VESICLES
GB9401309D0 (en) Improvements relating to syringes
ZA951420B (en) Therapeutic agents
EP0845990A4 (en) NEW USE OF PREGNANDIONS AS ANALGETICS
GB9006327D0 (en) Delivery of therapeutic agents
GB2331014C (en) Therapeutic uses of glucan
GB9417605D0 (en) Delivery of cytotoxic agents
GB9417939D0 (en) Improvements to comforts of chairs
GB9308679D0 (en) Improvements in or relating to drug receptors
GB9525891D0 (en) Therapeutic agents and their preparation